Cancer drug screening in patient-derived cells holds great promise for personalized oncology and drug discovery but lacks standardization. Whether cells are cultured as conventional monolayer or advanced organoid cultures influences drug effects and thereby drug selection and clinical success. To precisely compare drug profiles in differently cultured primary cells, we developed DeathPro, an automated microscopy-based assay to resolve drug-induced cell death and proliferation inhibition. Using DeathPro, we screened cells from ovarian cancer patients in monolayer or organoid culture with clinically relevant drugs. Drug-induced growth arrest and efficacy of cytostatic drugs differed between the two culture systems. Interestingly, drug effects in organoids were more diverse and had lower therapeutic potential. Genomic analysis revealed novel links between drug sensitivity and DNA repair deficiency in organoids that were undetectable in monolayers. Thus, our results highlight the dependency of cytostatic drugs and pharmacogenomic associations on culture systems, and guide culture selection for drug tests.
Introduction
Cell-based assays are a key tool in basic research and drug discovery, and are increasingly used in personalized oncology. In the last years, numerous anticancer therapeutics developed from standard cell line screens in conventional 2D culture failed in clinical studies 1 . As a result, standard treatment and overall survival of advanced cancers like ovarian cancer (OC) has not changed for decades 2 . To allow personalized therapy and improve drug development, new patient-derived models such as organoids [3] [4] [5] and patient-derived xenografts [6] [7] [8] that recapitulate the heterogeneity and intrinsic drug sensitivity of the original tumour have started to replace the popular cancer cell lines. Patient-derived organoids may be grown as 3D cultures on hydrogels like Matrigel that mimic the extracellular matrix. Compared to 2D cell cultures, they have emerged as near-physiological models reflecting the gene expression, differentiation and structure of the primary tissue 9 . Nevertheless, due to increased workload, higher costs and the current lack of 3D assay methods, most drug screens are still performed in less physiological 2D cultures 10 . Initial studies in ovarian and breast cancer showed that cells cultured as cell aggregates are less sensitive to drugs than in monolayer culture 11, 12 . The culture format thus shapes cellular drug responses and defines the translational power of a drug assay. However, this dependency cannot be studied in detail with widely-used, unspecific viability assays that measure metabolic activity or cellular ATP as surrogate markers. Such assays show limited reproducibility and do not resolve actual drug effects of high therapeutic interest such as cell death and growth arrest 3, 13 . Instead, recent advances in automated microscopy enable more sophisticated assays that can de-convolve drug effects in different culture formats.
Here, we systematically compare drug effects in organoid and standard 2D culture using DeathPro, a confocal microscopy based assay and image processing workflow to simultaneously study cell death and growth arrest in patient-derived material over time. Using DeathPro, we screened cells from nine high-grade serous OC patients with clinically relevant drugs and found that growth arrest and the efficacy of cytostatic drugs notably depends on the culture type. Remarkably, patient-specific genomic alterations correlated with drug effects observed in organoids, but not in 2D cell monolayers. Hence, combining refined assays like DeathPro with advanced models like cancer organoids could enhance drug screening in the context of personalized oncology and pharmacogenomics.
Results

De-convolving drug-induced cell death and proliferation inhibition
To resolve drug effects in patient cells and organoids, we developed an automated live cell assay and quantification workflow, which de-convolves drug-induced death and proliferation inhibition over time (DeathPro) ( Fig. 1 ). To this end, cells were stained with Hoechst and counterstained with propidium iodide (PI) for dead cells and analysed at consecutive time points by confocal microscopy. To accurately quantify cell growth for each condition 14 , cells were imaged at the start and end of the drug treatment at the same position. For high-throughput image analysis, we built an adaptable visual programming workflow that encompasses adaptive sequential thresholding and outlier filtering strategies to cope with heterogeneous cell morphologies and dye intensities. In the workflow, total areas covered by dead cells (PI-stained) and all cells (Hoechst or PI-stained) were determined from confocal images and used to calculate LD50 values and area under curve values for cell death (AUCd) and proliferation inhibition (AUCpi) (Fig. 1b ).
The DeathPro assay and workflow reliably resolved carboplatin-induced cell death and proliferation inhibition in OC patient-derived organoids (Fig. 1 ). In addition, we resolved drug effects in lung cancer organoids ( Supplementary Fig. 1 ) to verify that the DeathPro workflow can be applied to patient cells from different cancer entities.
By using live cell dyes, patient cells or organoids can be directly used for screening and do not have to be genetically modified to express fluorescent proteins. To exclude the possibility that either dye alters cell behaviour, we tested their effect on ovarian organoids. Hoechst and PI did not affect organoid growth but increased cell death ( Supplementary Fig. 2 ), which is accounted for in AUCd measurements by normalization to the untreated control ( Fig. 1b ). Imaging OC12 organoids only at the end or additionally at the beginning of the drug treatment did not alter organoid growth or cell death ( Supplementary Fig. 2 ). Cells are grown on Matrigel for 4 days, stained with Hoechst (H) and Propidium iodide (PI) and imaged at day 4, day 7 and day 10. Image gallery exemplifies OC12 organoid growth and cell death at start (day 4) and end of carboplatin treatment (day 7) and after carboplatin removal (day 10) using eight carboplatin concentrations or drug-free medium (ctrl). Confocal images are reduced to maximum intensity projections and binary images of merged Hoechst (green) and PI (red) channel are shown. (b) Image analysis for the DeathPro assay is based on area measurements in Hoechst and PI channels, and calculation of LD50, AUCd and AUCpi values to describe cell death and growth arrest. Drug response curve fitting and AUC values are illustrated for OC12 at 0 h and 72 h time points depicted in (a). Grey and orange boxes in (a) correspond to the magnifications in (b) . Scale bar is 200 µm.
Drug-induced growth arrest in ovarian cancer patient cells is culture-dependent
To systematically assess culture-type influence on patient cell responses, we used the DeathPro assay to screen patient-derived OC cell lines (PDCLs) cultured in standard 2D culture or as cancer organoids. PDCLs were established from metastatic serous ovarian cancers (FIGO stage   IIIc-IV, Supplementary Table 1 , Fig. 2a ). Additionally, we included Human Ovarian Surface Epithelial cells (HOSEpiC) to assess potential side-effects such as cytotoxicity in normal cells.
Seeded on Matrigel, HOSEpiC and PDCLs developed into spheres or morphologically diverse 'cancer organoids' (Fig. 2b) , respectively, with the latter retaining expression of the tumour markers CA-125 and WT1 ( Supplementary Fig. 3 ).
OC organoids or 2D cultured PDCLs were screened twice for 22 drugs or drug combinations (Supplementary Table 2 ) currently used or under investigation for treatment of OC. LD50 and cell death (AUCd) values were highly reproducible across all drugs and patients in 2D and organoid culture (Pearson correlation 0.86-0.97, Supplementary Fig. 4a ), whereas growth arrest (AUCpi) showed slightly lower correlation (Pearson correlation 0.67-0.76, Supplementary   Fig. 4b ).
Based on the DeathPro results, we compared all drug effects determined in OC patient cells between 2D and 3D culture ( Fig. 2c ). In both screens, drugs induced more growth arrest than cell death ( Fig. 2d ). Due to low drug-induced cell death, LD50 values could not be determined in 20-30% of all conditions ( Supplementary Fig. 5a ). After 72h drug treatment, cell death was slightly lower in organoids than in 2D cultures ( Fig. 2c , Supplementary Fig. 5b) . Surprisingly, death upon drug treatment strongly correlated in 2D and 3D culture whereas drug-induced growth-arrest varied greatly with culture type (Fig 2d, Pearson correlation 0.85 vs 0.475). Since drug-induced cell death was growth-dependent and organoids grew slowly compared to cells in 2D culture ( Supplementary Fig. 3c ), we measured organoid responses a second time after drug removal in 3D (Fig 2e, Supplementary Fig. 6a ). After wash out, drug effects were increased in most patient organoids ( Supplementary Fig. 6a -c) but cytotoxicity levels still resembled those in 2D culture ( Fig. 2f , Pearson correlation 0.755). Likewise, LD50s measured in 3D culture before and after drug removal highly correlated with LD50s in 2D culture ( Supplementary Fig. 5c, d , Pearson correlation 0.872, 0.822). In contrast, growth inhibition again differed after drug removal ( Fig. 2f , Pearson correlation 0.525). Overall, growth arrest was the major drug effect in OC cells and was culture-type dependent, whereas cell death was similar between culture types. 
Efficacy of cytostatic drugs depends on culture type
As the culture type affected growth arrest, the efficacy of cytostatic drugs that do not induce cell death should be culture-type dependent as well. Thus, we compared the efficacy of drugs in our panel by summarizing drug response parameters (LD50, AUCd and AUCpi) into a single efficacy measure, and clustering drugs on this basis. In 2D and 3D culture, three clusters arose based on differential cytotoxicity: (i) drugs effectively inducing cell death and growth inhibition (red cluster), (ii) medium cytotoxic drugs (yellow cluster) and (iii) ineffective drugs (blue cluster, Fig. 3a, b ). Clustering revealed that the most effective treatments (red cluster, Fig. 3a, b ) in both screens comprised belinostat, BKM120, the first-line therapeutic carboplatin and all combinations thereof. Paclitaxel, which forms part of the current first-line therapy for OC, was not among the most effective treatments tested due to its low toxicity in most patient cells ( Fig. 2c, e). Moreover, its combination with carboplatin performed no better than carboplatin alone in 2D and 3D ( Supplementary Fig. 6c, d) .
A fourth drug efficacy cluster appearing in 3D, but not in 2D culture, included four drugs that induced strong growth arrest but low cell death (green cluster, Fig. 3a, b ). All four drugs, ICG-001, temsirolismus, AZD5363 and AZD2014, targeted proliferation pathways and were more effective in 3D culture. To differentiate between these and other drugs, we divided our panel into 'cytostatic drugs' inhibiting kinases or other effectors of proliferation pathways and 'cytotoxic drugs' causing DNA damage, DNA methylation changes or mitotic failure.
The effects of four specific drugs and one drug combination were significantly altered in 3D compared to 2D before and after drug removal ( Fig. 3c, d ): Sarcoma (SRC) kinase inhibitor dasatinib induced significantly lower cell death and growth arrest in OC organoids than in monolayer patient cells ( Fig. 3e ). In combination with carboplatin and paclitaxel, growth arrest in organoids was still lower than in 2D. In contrast to dasatinib, the mTOR inhibitors temsirolismus and AZD2014 inhibited cell growth in organoids more strongly than in 2D culture. Azacytidine was the only cytotoxic drug that induced lower growth arrest in organoids than in cells in 2D. As azacytidine induced comparable cell death in 2D and 3D ( Fig. 2c, e ), its overall efficacy was similar in 2D and 3D culture (yellow, medium cytotoxic cluster Fig. 3a ). In both screens we found that belinostat, BKM120 and carboplatin were the most potent drugs and that the efficacy of the cytostatic drugs dasatinib, temsirolismus and AZD2014 depended on culture type. 
Drug responses in patient organoids are more diverse and of lower therapeutic potential
Having compared drug effects generally and separately, we inspected differences and similarities of patient cell responses in 2D and 3D culture by hierarchical clustering. Interestingly, drug response profiles tended to cluster based on the patients as well as the culture format ( Fig.   4a ), indicating that culture type can influence patient cell responses to the same extent as intrinsic tumour heterogeneity. Most 2D patient profiles clustered together homogenously, with the exception of OC12 and OC18 which showed comparable response profiles in 2D and 3D. In total, we found 2D drug profiles in 4 subclusters while 3D drug profiles occurred in 8 subclusters, demonstrating once more that drug profiles appear more diverse in organoids. Normal HOSEpiC cells clustered separately from patient cells in 3D but showed a drug response similar to OC19 in 2D, suggesting that the culture format can conceal differences in genomic aberrations and gene expression.
In our screens, we included ovarian epithelial cells (HOSEpiC) to examine cytotoxicity induced in noncancerous cells. To normalize drug efficacy in PDCLs to HOSEpiC, we calculated the therapeutic index (TI) as the ratio of LD50 values from PDCL and HOSEpiC in both cultures ( Fig. 4b ). TI patterns in cancer organoids were less favourable overall than in 2D culture (blue colour, Fig. 4b ). The most effective candidates, carboplatin and belinostat, had positive TIs and low toxicity, while low TIs for BKM120 reflected high toxicity in normal cells. To identify patientspecific treatment options, the drug with the highest TI can be selected for each individual, e.g. MK5108 for OC12. For some patient cells, e.g. Asc14, belinostat would be suggested from organoid testing but not from 2D cell testing where cell death was too low to determine an LD50.
Even if drug-induced cytotoxicity differed only minimally between 2D and 3D cultured patient cells ( Fig. 2, Supplementary Fig. 5 ), therapeutic potentials in OC patient organoids were altered distinctively. By taking into account the heterogeneity in drug responses, our DeathPro assay allows the systematic deduction of patient-specific treatment options across cell cultures and patient cell lines. 
Patient cells harbour numerous copy number alterations not linked to drug-induced cell death
To predict or functionally link drug sensitivities to genetic alterations, several studies have integrated drug sensitivity data from viability assays of patient cells or cell lines with genome sequencing data 3, 4, 15 . Here, we performed whole genome sequencing (WGS) to associate OC genotypes with drug sensitivity data. First, we confirmed that genetic alterations in our PDCL set matched those observed in tumours: We found multiple copy number alterations (CNA) in all PDCLs (Fig. 5a ), as previously reported for serous OC 16 . In a set of OC-relevant genes selected from literature [17] [18] [19] and databases 20, 21 , few deletion/insertion polymorphisms (indels) or mutations were detected, except for TP53, which was mutated with a similar frequency as in the COSMIC cohort ( Fig. 5b) . Likewise, genes frequently amplified (MYC, PIK3CA and AURKA) or lost (RB1, PTEN) in ovarian tumours 19 were also commonly multiplied or lost in our set of patient cells (Fig.   5b ). Since drug sensitivity frequently correlates with alterations in the corresponding drug target 15 , we associated target genes commonly affected by CNAs with cell death (AUCd) induced by the respective inhibitor. Amplifications of AURKA and PI3KCA did not alter cytotoxicity induced by AURKA inhibitor MK5108 or PI3K inhibitor BKM120, respectively ( Fig. 5 c, d). Moreover, loss of BRCA1/2, a putative marker for impaired DNA repair capacity 22 , did not affect sensitivity towards the DNA damage related drugs carboplatin and olaparib (Fig. 5e, f ). 
Homologous recombination deficiency scores correlate with drug effects in organoids
To incorporate the complex genomic aberrations in OC, we focused on the genome structure altered by DNA repair deficiencies. Loss of heterozygosity regions can be counted and added up to the homologous recombination deficiency (HRD) score (Fig. 6a ) which is linked to cellular HR repair capacity 22 . HRD scores in our OC set varied between 3 and 22 (Fig. 6b ). We systematically associated HRD scores and OC drug responses in different culture systems and found 20 statistically significant correlations (Rsquare >0.61, false discovery rate <0.1, Fig. 6c ).
Remarkably, 90% (18/20) of these potentially relevant associations were observed with 3D culture derived data. HRD scores correlated not only with cytotoxic responses to carboplatin and all its combinations ( Fig. 6c, d ) but also with paclitaxel, azacytidine and decitabine responses although these drugs did not directly affect DNA structure or repair ( Fig. 6e, f, g) . Moreover, HRD scores were linked to growth arrest induced by temsirolismus ( Fig. 6d ). Stratification based on high (>=10) or low (<10) HRD scores divided OC cells into responders (OC12, OC18 and PE20) and non-responders to carboplatin, olaparib or azacytidine (Fig. 6d, f, Supplementary   Fig. 7a ). The OC responders grew faster than non-responders in organoid but not in 2D culture ( Fig. 2c, d , Supplementary Fig. 7 b, c) . Thus, high HRD scores co-occurred not only with high drug-induced cytotoxicity but also with fast growth in organoids. Altogether, the strong correlation of growth and HRD scores with drug response in cancer organoids supports our view that organoids are a better model to assess patient specific drug response in vitro. 
Discussion
In this study, we systematically compared drug responses between 2D and organoid cultures of patient cells and their association to genomic alterations. For this purpose we developed DeathPro, an automated microscopy-based workflow that simultaneously discriminates cytotoxic and cytostatic drug effects over time. Previous microscopy-based drug assays in 3D cell cultures or organoids focused on morphological changes 23, 24 , metabolic parameters 25 or required specific instrumentation to resolve cell death and growth 25, 26 . Tested in a small number of cell models and not in parallel in 2D cultures, the usability and scalability of these assays is limited [24] [25] [26] Resolving drug effects in OC patient cells, we found that drug-induced cell death was similar in both culture types whereas growth arrest varied. Accordingly, the efficacy of cytostatic drugs like dasatinib, temsirolismus or AZD2014 was culture type-dependent. Since most newly developed drugs are cytostatic 28 , our results highlight the importance of choosing the right model system to evaluate drug efficacy e.g. in preclinical studies. In particular, our results reveal diverse drug responses in organoids and suggest that specific drug response phenotypes are visible in organoids but not in monolayer culture. We observed less cell death in 3D compared to 2D cultures after 72h but higher death after drug removal (114h), which may lead to an underestimation of drug effects in 3D after a 72h standard treatment interval. The previously reported findings that standard cell lines in 3D culture are more chemoresistant than in 2D culture 10, 29 may therefore in part reflect altered cell death kinetics, which should be accounted for in future screens. Interestingly, the observed drug effects in OC patient cells mirrored findings from clinical trials. The combination of carboplatin and paclitaxel did not perform better than carboplatin alone, consistent with the ICON 3 trial 30 . Paclitaxel killed only 2 of 9 patient cancer organoids, similar to taxol monotherapy studies in metastatic or refractory OC that reported 20% responders 31, 32 . Dasatinib, which failed at clinical phase II for recurrent OC and primary peritoneal carcinoma 33 , was effective in 2D but ineffective in 3D culture in our screen. From the drugs included in our panel, no candidate surpassed the first-line therapeutic carboplatin with regard to (i) efficacy in the whole patient set and (ii) limited toxicity in normal epithelial cells. Still, initial cytotoxicity profiles determined with DeathPro readily suggested patient-specific alternatives to carboplatin, such as Aurora kinase A inhibitor MK5108 for chemosensitive patient OC12 or belinostat for chemoresistant Asc14.
By associating resolved drug responses in OC patient cells with HRD scores from WGS data, we found a set of relevant correlations which would not be detected with proliferation-based assays in 2D. As expected based on a study that linked higher platinum sensitivities to HR deficiency 34 , carboplatin-induced cytotoxicity correlated with HRD scores in OC patients.
Moreover, we detected correlations of DNA demethylating drug effects with HRD scores, suggesting a link between deficient DNA homologous recombination repair and DNA demethylation. While only decitabine sensitivity has been linked to KRAS status so far 35 , there is increasing evidence that both azacytidine and decitabine induce reactive oxygen species which cause DNA damage and finally apoptosis in cancer cells [36] [37] [38] . For all drugs whose effects correlated with HRD score, we observed a stronger correlation in OC cancer organoids than in monolayer culture. Interestingly, cell growth, HRD score and drug-induced cytotoxicity were linked in organoids but not in 2D cell culture. Similar to drug efficacy, this suggests that genotype-drug sensitivity correlations are more pronounced in 3D cultures, which is particularly important since comprehensive studies so far have focused on 2D culture data 15, 39 .
Taken together, we developed and provide the DeathPro assay as a tool for refined drug screening and for deciphering genotype-drug sensitivity associations, and found that culture type was a key determinant of the efficacy of cytostatic drugs. In our hands, drug sensitivity was not generally decreased in organoids as previous studies suggested; instead, drug responses were more diverse and correlated better with genomic alterations in 3D compared to 2D culture.
Overall, these results could provide a rationale to select the appropriate culture format for drug sensitivity assays in basic and future translational research. Declaration; written informed consent was obtained from all patients. Primary serous ovarian carcinoma cell lines were established by transplantation of primary tumour specimen or tumour cells as previously described 40, 41 . Defined-serum-free culture medium was used as previously described 41 with the addition of 36 ng/ml hydrocortisone, 5 µg/ml insulin and 0.5 ng/ml betaestradiol. HOSEpiC cells were obtained from ScienCell Research. PDCLs were checked for cross-contamination with standard OC cell lines and tested for mycoplasma contamination using the commercial Multiplex Cell Line Authentication and Mycoplasma Test Services (Multiplexion, Heidelberg, Germany). OC22 WGS data contained ~30% reads mapping to the mouse genome due to irremovable, immortalized mouse fibroblasts potentially derived from the mouse xenograft. We used the 70% human sequences for further analysis. WGS data of all other PDCLs and HOSEpiC contained only human DNA sequences. All OC cells were cultured in Primaria flasks, subcultured using StemPro Accutase (ThermoFischer) and used at passages below 20 (PDCLs) or 6 (HOSEpiC). The cell lines LN2106 and T2427 were generated from human squamous cell carcinomas as described previously 42 Medium for drug treatment contained 1 µg/ml Hoechst (Invitrogen) and 1 µg/ml PI (Sigma) and was added one day (2D) or four days (3D) after cell seeding and substituted after 72 h by drugfree medium in 3D. Cells were exposed maximally to 1% DMSO or 1% ethanol in the highest drug concentrations and corresponding controls were included in the assay. Cells were imaged at similar positions after 0 h, 72 h and 144 h (only 3D) after start of drug treatment using a Zeiss LSM780 confocal microscope, 10x objective (EC Plan-Neofluar 10x/0.30 M27) and 405 nm and 561 nm diode lasers in simultaneous mode. Imaging was performed in an incubation chamber at 37 °C, 5% CO 2 and 50-60% humidity using the Visual Basic for Applications macro 'AutofocusScreen' 43 .
Materials and Methods
Patient-derived cell lines and drugs
Image processing and drug response analysis
Image stacks were processed to maximum intensity projections (MIPs) with a custom-built macro in Fiji 2.0.0-rc-19/1.49m 44 . MIPs were uploaded and processed in our 'DeathPro' workflow in KNIME 3.1 (Konstanz Information Miner-47). Images were annotated with drugs and concentrations used and signals were extracted by thresholding. For the calculation, summarizing, clustering and plotting of values R version 3.3.2 46 including packages drc 47 , stringr, ComplexHeatmap 48 , ggplot2 49 , reshape 50 and RColorBrewer 51 were used.
Hierarchical clustering with Euclidian distance and complete linkage was applied to compare PDCL-specific drug response profiles consisting of cell death (AUCd) and growth arrest (AUCpi)
values measured over all drugs tested. Average linkage was used for drug response parameters averaged over all PDCLs.
Whole Genome Sequencing and Analysis
Genomic DNA from 1x10 6 primary cells was extracted using the DNeasy Blood & Tissue Kit (Qiagen), prepared with the TruSeq PCR free library kit (Illumina) and sequenced on a HiSeq X Ten (Illumina). Sequences were mapped to the human reference genome (build hg19, version hs37d5) 52 using bwa-mem 0.7.8-r455 53 . The OC22 sample contained ~30% mouse gDNA and thus had to be aligned to the hs37d5-mm10 hybrid reference sequence. Only reads mapped against hs37d5 were used for further analysis. Duplicates were marked with Picard 1.125 (https://broadinstitute.github.io/picard/). Somatic nucleotide variations and indels were called without matched control using our in-house workflow 54 , filtered 55 and annotated with Annovar 56 .
Copy number variations and loss of heterozygosity regions were determined by dedicated workflows and gains and losses were classified based on estimated ploidies. Homologous recombination deficiency scores were determined as previously described 22 . Sequence data has been deposited at the European Genome-phenome Archive (http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under accession number EGAS00001002239.
Statistical Analysis
Independent replicates refer to independent cell samples seeded, treated and imaged on different days. Differences between effects of drug combinations and single drugs were tested for statistical significance using a paired Student's t-test. Differences between responses of different groups to one drug were assessed with a two-sided Welch's t-test. P values <0.05 were considered statistically significant and indicated with asterisks. Pearson's correlation coefficient (Rp) was used to describe the strength of correlation between biological replicates. Coefficient of determination (R 2 ) was used to denote strength of linear relationships between area under curve values and HRD scores. False discovery rate for R 2 was determined by random sampling. 
